User:Mr. Ibrahem/Abaloparatide

Abaloparatide, sold under the brand name Tymlos among others, is a medication used to treat osteoporosis after menopause. In those at high risk, it may decrease the risk of fractures from 5.9% to 3.3%. It should not be used for more than two years. It is used as an injection just under the skin.

Common side effects palpitations, lightheadedness, nausea, headache, tiredness, and upper abdominal pain. Other potential concerns include an increased risk of osteosarcoma, high blood calcium, low blood pressure with standing, and pain at the injection site. It is a parathyroid hormone-related protein (PTHrP) analog and works by promoting bone growth.

Abaloparatide was approved for medical use in the United States in 2017. It was initially denied approval in Europe in 2018; however, was subsequently approved in 2022. As of 2018, it cost about 1,800 USD per month in the United States. As of 2019 it is unclear how its effectiveness compares to the less expensive bisphosphonates.